<DOC>
	<DOCNO>NCT00559052</DOCNO>
	<brief_summary>EPI lead maldigestion frequent find many disease pancreas , chronic pancreatitis ( CP ) . Steatorrhea important digestive manifestation EPI . The current treatment EPI include enzyme supplementation porcine pancreatic enzyme concentrate , consist mainly lipase , amylase protease . An enzyme preparation able deliver appropriate enzyme level duodenum instead mid gut distal small bowel , would appear clinically efficacious treatment steatorrhea subject CP suffer EPI .</brief_summary>
	<brief_title>An Open-Label Study Evaluate Intraduodenal Delivery Enzymes From Administration VIOKASE16 Exocrine Pancreatic Insufficiency ( EPI )</brief_title>
	<detailed_description>Day screening : Subjects undergo screen procedure prior entry study . Day 0 : Subjects admit facility . Day 1 : Subjects undergo first perfusion/aspiration procedure . Day 2 : Subjects rest . Day 3 : Subjects undergo second perfusion/aspiration procedure . Day 4 : Subjects discharge .</detailed_description>
	<mesh_term>Exocrine Pancreatic Insufficiency</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<mesh_term>Pancreatin</mesh_term>
	<criteria>Subjects must ability give informed consent Female subject must use medically acceptable form birth control negative pregnancy test upon enter study breastfeed Subjects must medical condition compatible exocrine pancreatic insufficiency Subjects must therapeutic dos pancreatic enzyme supplementation prior study entry day Subjects must omeprazole least 5 day prior Day 0 . Subjects know hypersensitivity and/or contraindication VIOKASEÂ®16 nonactive component VIOKASE protein porcine origin Subjects know hypersensitivity and/or contraindication omeprazole nonactive component omeprazole Subjects enzyme therapy , H2receptor antagonists , anticholinergic , antispasmodic prior study entry Female subject pregnant lactate Subjects acute pancreatitis acute exacerbation chronic pancreatic disease Subjects history solid organ transplant significant bowel resection esophagus pancreas Subjects receive investigational new drug within 30 day prior entry study . Subjects know coagulopathy Subjects abnormal liver function test Subjects know significant medical and/or mental disease would compromise subject 's welfare confound study result Subjects omeprazole least 5 day prior Day 0</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>Enzymes</keyword>
	<keyword>VIOKASE</keyword>
	<keyword>Bioavailability</keyword>
</DOC>